Director at Labcorp (NYSE: LH) receives 773 RSUs grant

Rhea-AI Filing Summary

Labcorp Holdings Inc. director Garheng Kong reported an equity award of restricted stock units. On February 10, 2026, Kong acquired 773 Restricted Stock Units, each representing the right to receive one share of Labcorp common stock. These units vest fully on February 10, 2027.

Following this grant, Kong beneficially owns 1,670 Restricted Stock Units, held directly. This filing reflects a stock-based compensation award rather than an open-market purchase or sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kong Garheng

(Last) (First) (Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON NC 27215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/10/2026		A		773		(2)	(2)	Common Stock	773	$0	1,670(3)	D

Explanation of Responses:

1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

2. The Restricted Stock Units vest fully on February 10, 2027.

3. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Kathryn W. Kyle, Attorney-in-Fact for Garheng Kong	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Labcorp (LH) director Garheng Kong report?

Labcorp director Garheng Kong reported an equity award of restricted stock units. On February 10, 2026, he acquired 773 Restricted Stock Units as compensation, not through an open-market trade, each representing one share of Labcorp common stock when vested.

How many Labcorp (LH) restricted stock units does Garheng Kong now hold?

After the reported award, Garheng Kong beneficially owns 1,670 Restricted Stock Units. This figure represents the aggregate number of restricted stock units he holds directly, as disclosed in the Form 4, and reflects his total unvested equity compensation position in these units.

When do Garheng Kong’s new Labcorp (LH) restricted stock units vest?

The newly granted Labcorp restricted stock units to director Garheng Kong vest fully on February 10, 2027. Vesting means he becomes entitled to receive Labcorp common shares, one share for each unit, assuming continued satisfaction of the award’s conditions.

Was Garheng Kong’s Labcorp (LH) Form 4 transaction a purchase or a grant?

The Form 4 shows a grant or award, not a market purchase. Transaction code “A” indicates an acquisition of 773 Restricted Stock Units as compensation, at a reported price of $0 per unit, consistent with stock-based awards to directors.

What type of security did Labcorp (LH) director Garheng Kong receive?

Garheng Kong received Restricted Stock Units, a form of stock-based compensation. Each unit represents the contingent right to receive one share of Labcorp common stock upon vesting, aligning director incentives with shareholder interests over time.